RecruitingNot ApplicableNCT06277180

68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC

Evaluating the Clinical Value of 68Ga-TCR-FAPI PET/CT to Guide the Surgical Treatment for Medullary Thyroid Carcinoma (MTC)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

50 participants

Start Date

Oct 1, 2023

Study Type

INTERVENTIONAL

Conditions

Surgery Fibroblast Activation Protein Inhibitor Medullary Thyroid Cancer Prositron Emission Tomography

Summary

This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a specialized PET/CT scan using a new imaging agent (68Ga-TCR-FAPI) can more precisely locate all medullary thyroid cancer (MTC) tumors before surgery, helping surgeons remove the cancer more completely and accurately. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with medullary thyroid cancer (MTC) and have a surgical indication - Your cancer may be newly diagnosed or previously treated - Your major organs are functioning adequately - You are willing and able to give informed consent **You may NOT be eligible if...** - You have a history of allergic reactions to imaging agents - You have conditions preventing PET-CT scanning - You are pregnant or breastfeeding - You refuse surgery or the guided imaging procedure - Your cancer is not suitable for surgical removal Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESurgery

Surgery is performed based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, and all 68Ga-TCR-FAPI-avid lesions are resected.

PROCEDURESurgery

68Ga-TCR-FAPI PET/CT identified distant metastasis or unresectable lesions, but the patient is still recommended to undergo surgery for debulking or reduce symptoms.

Locations(1)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06277180